Experts suggest the FDA’s Advanced Manufacturing Technologies designation could be a lifeline for improving production ...
Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau ...
We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, ...
NervGen will meet with the FDA early next year to align on a regulatory path forward for NVG-291 in chronic spinal cord ...
Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or ...
Sanjula Jain-Nagpal, associate director of Policy & Research Strategy at the FDA, will be allowed to remain at the agency but ...
Asundexian’s Phase III win could also bode well for Bristol Myers Squibb, which is also developing a Factor XIa inhibitor called milvexian for stroke prevention, analysts said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback